Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79915.510.0938%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Cardiol Therapeutics Inc

CRDLNASDAQ
Trade with Public
Trade with Public
$2.20
0.041.85%
At close: Sep 4, 5:00 PM EST
$2.20
N/A
After Hours: Sep 4, 6:04 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentCompareOptionsStock Report

Cardiol Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cardiol Therapeutics (CRDL).

Price Target Range — 8 Quarters

Analyst Consensus — 3 Analysts

3Buy
Consensus RatingBuy# Analysts3Avg. Consensus PT$10Upside to Avg. PT+331.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 17, 2026Canaccord GenuityEdward NashPT RaiseBuy$8→$10
Jul 14, 2026HC Wainwright & Co.Brandon FolkesMaintainedBuy$9
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $10

Canaccord Genuity analyst Edward Nash maintains Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and raises the price target from $8 to $10.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
Benzinga Newsdesk

This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Avi Kapoor

PRO
HC Wainwright & Co. Initiates Coverage On Cardiol Therapeutics with Buy Rating, Announces Price Target of $9

HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Cardiol Therapeutics (NASDAQ:CRDL) with a Buy rating and announces Price Target of $9.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved